TABLE 1.
Down-selected Env gp120 and gp140 antigens and down-selected V1V2 antigens
| Antigen group or name | Medoid | Subtype | Country of origin | Gender of source | Mode of transmission or contact | Fiebig stage(s)c | Year |
|---|---|---|---|---|---|---|---|
| gp120 Enva | |||||||
| 51802_D11gp120 | 5 | A | Kenya | Male | Homosexual | I | 2009 |
| A244 D11gp120 | 6 | CRF01_AE | Thailand | Male | Homosexual | VI | 1990 |
| 254008_D11gp120 | 7 | CRF01_AE | Thailand | Male | Homosexual | II | 2009 |
| BORI_D11gp120 | 1 | B | USA | Male | Homosexual | II | 1990 |
| TT31P.2792_D11gp120 | 3 | B | Trinidad/Tobago | Female | Heterosexual | II | 1998 |
| B.6240_D11gp120 | 8 | B | USA | Male | Unknown | II | 1995 |
| CNE20_D11gp120 | 2 | CRF07_BC | China (Xinjiang) | Unknown | Heterosexual | VI | 2007 |
| BJOX002_D11gp120 | 4 | CRF07_BC | China (Beijing) | Male | Intravenous drug use | I-II | 2007 |
| gp140 Enva | |||||||
| 9004S.gp140C | 4 | A | Uganda | Female | Heterosexual | IV | 2007 |
| AE.01.con_env03 gp140CF | 6 | Consensus AE | |||||
| SC42261_gp140 | 7 | B | Trinidad/Tobago | Male | Heterosexual | IV | 1995 |
| WITO4160.gp140C | 9 | B | USA | Male | Heterosexual | II | 2000 |
| RHPA4259_C7.gp140C | 1 | B | USA | Female | Heterosexual | I-IV | 2000 |
| 1086C gp140C | 2 | C | Malawi | Male | Heterosexual | I-II | 2004 |
| C.CH505TF_gp140 | 3+ | C | Malawi | Male | Heterosexual | IV | 2008 |
| BF1266_gp140C | 3 | C | Malawi | Unknown | Breastfeeding | I-II | 2002 |
| V1V2 Envb | |||||||
| gp70-191084_B7 V1V2 | 5+ | A | Uganda | Female | Heterosexual | IV | 2007 |
| gp70-C2101.c01_V1V2 | 3 | CRF01_AE | Thailand | Female | Heterosexual | ND | 1999 |
| gp70-CM244.ec1 V1V2 | 4 | CRF01_AE | Thailand | Male | Heterosexual | VI | 1990 |
| gp70-700010058 V1V2 | 1 | B | USA | Male | Unknown | III | 2006 |
| gp70-RHPA4259.7 V1V2 | 11 | B | USA | Female | Heterosexual | I-IV | 2000 |
| gp70-62357.14 V1V2 | 12 | B | USA | Male | Unknown | II | 1996 |
| gp70_B.CaseA_V1_V2 | 13 | B | USA | Male | Homosexual | VI | 1988–1989 |
| gp70-TT31P.2F10.2792 V1V2 | 14 | B | Trinidad/Tobago | Female | Heterosexual | II | 1998 |
| gp70-BJOX002000.03.2 V1V2 | 7 | CRF07_BC | China (Beijing) | Male | Intravenous drug use | I-II | 2007 |
| gp70-7060101641 V1V2 | 2 | C | South Africa | Male | Heterosexual | III | 2007 |
| gp70-Ce1086_B2 V1V2 | 4+ | C | Malawi | Male | Heterosexual | I-II | 2004 |
| gp70-96ZM651.02 V1v2 | 6 | C | Zambia | Male | Unknown | VI | 1996 |
| gp70-001428.2.42 V1V2 | 8 | C | India | Female | Heterosexual | IV | 2000 |
| gp70-CAP210.2.00.E8 V1V2 | 9 | C | South Africa | Female | Heterosexual | IV | 2005 |
| gp70-BF1266_431a_V1V2 | 10 | C | Malawi | Unknown | Breastfeeding | I-II | 2002 |
| gp70-TV1.21 V1V2 | 13+ | C | South Africa | Male | Heterosexual | VI | 1998 |
a
Down-selected Env gp120 and gp140 antigens: 8 gp120 and 8 gp140 envelope proteins were down-selected by the PAM analysis and cross-validation. These envelope proteins comprise subtypes A, AE, B, BC, and C from diverse geographic regions and include circulating T/F strains.
b
Down-selected V1V2 antigens: 16 V1V2 antigens were down-selected based on the PAM analysis and cross-validation. These V1V2 antigens cover subtypes AE, A, B, BC, and C from diverse geographic regions.
c
ND, not determined. +, antigen selected as alternative to cluster medoid.